Innovotech Announces New Senior Management

Innovotech Inc. (TSX VENTURE:IOT), an innovator focused on providing new and
practical solutions to medical, agricultural and industrial problems caused by
microbial biofilms, today announced the appointment of Dr. Amin Omar to the new
position of General Manager. Mr. Ken Boutilier has stepped down as President and
CEO of Innovotech, effective January 1, 2014 and Dr. James Timourian has been
appointed to the position of President. Mr. Bruce Hirsche will continue as
Secretary and Dr. James Timourian will continue as Chairman of the Board.


"Dr. Amin Omar, with Innovotech since 2007, has been responsible for building
Innovotech's outstanding reputation of scientific and regulatory expertise in
the field of infection control. We have confidence that the management team we
now have in place will successfully lead Innovotech through the coming phases of
its development. The Company will continue to focus on expanding its revenue
services and developing significant markets for its most promising
technologies," said Dr. James Timourian, Chairman of the Board. "We greatly
appreciate Ken's service to Innovotech and wish him good fortune in his future
endeavors."


About Innovotech Inc:

Innovotech Inc. is an innovator in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are organized
communities of microorganisms that exist in virtually every natural environment
and are responsible for a host of diseases in human health, animal health and
agriculture. There are few products or regulatory standards, aside from those of
Innovotech, designed specifically for biofilm-forming organisms.


Innovotech has a range of products that address the issue of biofilms within a
number of different industries, including commercially available products in a
variety of market segments; the MBEC Assay(TM), InnovoSIL(TM), bioFILM PA(TM),
InnovoSCEPT(TM)-Human and InnovoSCEPT(TM)-Veterinary tests. The MBEC Assay(TM)
is a high throughput biofilm growth device that is an ASTM International
standard. InnovoSIL(TM) is a family of silver-based antimicrobials promising
superior performance for medical device coatings and wound dressings, bioFILM
PA(TM) and InnovoSCEPT(TM)-Human are the first diagnostic tests to assist
physicians in the selection of the most effective antibiotic treatment for
patients with biofilm-based chronic infections, while the
InnovoSCEPT(TM)-Veterinary tests are designed to determine the most effective
antibiotic treatment for chronic infections in both large and small animals


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.


The TSX Venture Exchange does not accept responsibility for the adequacy or
accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Innovotech Inc.
Dr. James Timourian
President
780.448.0585 ext 221
james.timourian@innovotech.ca
www.innovotech.ca
Innovotech (TSXV:IOT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024